I'm only a new shareholder, but it seems to me that ARX's main issue is that our revenue is too dependent on TELA, and they are a small - and seemingly half-baked - company. ARX is trying to navigate away from this by ramping up the in-house sales team - but that takes time.
Brian Ward is heavily invested in ARX, and it's his baby, so I think he has our best interests in mind. But he chose the wrong partner in TELA, and that is something that must be addressed at some point. Hopefully, TELA will still meet their guidance of near 30% growth, but it's hard to see how based on these recent results?
poor TELA bio results, page-3
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
53.0¢ |
Change
0.010(1.92%) |
Mkt cap ! $182.7M | |||
| Open | High | Low | Value | Volume |
| 52.0¢ | 53.0¢ | 51.0¢ | $37.41K | 72.48K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13980 | 50.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.0¢ | 14165 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| ARX (ASX) Chart |